A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

OA Location

https://www.repository.cam.ac.uk/handle/1810/256264

Author(s)

Scott, RA

Freitag, DF

Li, L

Chu, AY

Surendran, P

more

Type

Journal Article

Date Issued

2016-06-01

Date Acceptance

2016-05-10

Citation

Science Translational Medicine, 2016, 8 (341), pp.341ra76-341ra76

URI

http://hdl.handle.net/10044/1/38461

DOI

https://www.dx.doi.org/10.1126/scitranslmed.aad3744

ISSN

1946-6242

Publisher

American Association for the Advancement of Science

Start Page

341ra76

End Page

341ra76

Journal / Book Title

Science Translational Medicine

Volume

8

Issue

341

Copyright Statement

This is the author accepted manuscript. The final version is available from the American Association for the Advancement of Science via http://dx.doi.org/10.1126/scitranslmed.aad3744

Subjects

Science & Technology

Life Sciences & Biomedicine

Cell Biology

Medicine, Research & Experimental

Research & Experimental Medicine

GLUCAGON-LIKE PEPTIDE-1

TYPE-2 DIABETES-MELLITUS

PLACEBO-CONTROLLED TRIAL

RECEPTOR AGONIST LIXISENATIDE

ONCE-DAILY LIXISENATIDE

RANDOMIZED CONTROLLED-TRIAL

INCRETIN-BASED THERAPIES

BETA-CELL FUNCTION

BODY-MASS INDEX

DOUBLE-BLIND

CVD50 consortium

GERAD_EC Consortium

Neurology Working Group of the Cohorts for Heart

Aging Research in Genomic Epidemiology (CHARGE)

Alzheimer’s Disease Genetics Consortium

Pancreatic Cancer Cohort Consortium

European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD)

EPIC-InterAct

CHARGE consortium

CHD Exome+ Consortium

CARDIOGRAM Exome Consortium

11 Medical And Health Sciences

06 Biological Sciences

Publication Status

Published